

Haibiao Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/827756/publications.pdf>

Version: 2024-02-01

17
papers

371
citations

1040056

9
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

585
citing authors

#	ARTICLE	IF	CITATIONS
1	LncRNA MALAT1 Inhibits Apoptosis and Promotes Invasion by Antagonizing miR-125b in Bladder Cancer Cells. <i>Journal of Cancer</i> , 2017, 8, 3803-3811.	2.5	79
2	TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss. <i>Cancer Discovery</i> , 2020, 10, 460-475.	9.4	63
3	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. <i>Molecular Cell</i> , 2020, 77, 1294-1306.e5.	9.7	41
4	Long non-coding RNA CRNDE in cancer prognosis: Review and meta-analysis. <i>Clinica Chimica Acta</i> , 2018, 485, 262-271.	1.1	38
5	SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers. <i>Tumor Biology</i> , 2017, 39, 101042831771140.	1.8	34
6	Colon cancer associated transcripts in human cancers. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 531-540.	5.6	32
7	Synthesizing a Genetic Sensor Based on CRISPR-Cas9 for Specifically Killing p53-Deficient Cancer Cells. <i>ACS Synthetic Biology</i> , 2018, 7, 1798-1807.	3.8	24
8	Oestrogen promotes tumorigenesis of bladder cancer by inducing the enhancer RNA eGREB1. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5919-5927.	3.6	15
9	Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells. <i>Molecular BioSystems</i> , 2017, 13, 1597-1607.	2.9	12
10	High expression of enhancer RNA MARC1 or its activation by DHT is associated with the malignant behavior in bladder cancer. <i>Experimental Cell Research</i> , 2018, 370, 303-311.	2.6	7
11	A revolutionary tool: CRISPR technology plays an important role in construction of intelligitized gene circuits. <i>Cell Proliferation</i> , 2019, 52, e12552.	5.3	7
12	Synthetic artificial "long non-coding RNAs" targeting oncogenic microRNAs and transcriptional factors inhibit malignant phenotypes of bladder cancer cells. <i>Cancer Letters</i> , 2018, 422, 94-106.	7.2	6
13	Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients. <i>Journal of Medical Genetics</i> , 2022, 59, 951-956.	3.2	5
14	Lentivirus-mediated shRNA targeting <i>MUTYH</i> ; inhibits malignant phenotypes of bladder cancer SW780 cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6101-6109.	2.0	4
15	Role of nuclear paraspeckle assembly transcript 1 as a common molecular marker for prognosis in various cancers. <i>Minerva Medica</i> , 2017, 108, 477-479.	0.9	2
16	A systematic review and meta-analysis of long noncoding RNA linc-UBC1 expression and prognosis and clinicopathological phenotypes in human cancers. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2020, 48, 875-884.	2.8	1
17	Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. <i>Journal of Medical Genetics</i> , 2020, 57, 744-751.	3.2	1